Paltusotine
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
New and emerging pharmacological treatment options for acromegaly: a 2026 update.
Journal: Expert opinion on pharmacotherapy
Published: October 15, 2026
Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults.
Journal: Clinical pharmacology in drug development
Published: May 14, 2026
Safety and Efficacy of Once-Daily Oral Paltusotine in Acromegaly: ACROBAT Advance Open-Label Extension Up to 4 Years.
Journal: The Journal of clinical endocrinology and metabolism
Published: March 03, 2026
Developments in Pharmacotherapy for Acromegaly: Current and Emerging Approaches.
Journal: Drugs
Published: January 30, 2026
Current treatment landscape of acromegaly.
Journal: The Journal of clinical endocrinology and metabolism
Published: January 26, 2026
Efficacy and safety of pharmacologic therapies in acromegaly: a systematic literature review and network meta-analysis.
Journal: The Journal of clinical endocrinology and metabolism
Published: December 23, 2025
Paltusotine and Its Place in the Treatment Armamentarium for Acromegaly.
Journal: The Journal of clinical endocrinology and metabolism
Published: November 22, 2025
A new era in oral treatment for acromegaly with the FDA-approved drug paltusotine.
Journal: Annals of medicine and surgery (2012)
Published: November 11, 2025
Paltusotine Hydrochloride.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: November 09, 2025
Paltusotine: The first selective nonpeptide agonist of somatostatin receptor 2 (SSTR2) for the treatment of acromegaly.
Journal: Drug discoveries & therapeutics
Published: October 29, 2025
Last Updated: 11/08/2026